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UNCERTAINTIES
How effective are platelet rich plasma injections in
treating musculoskeletal soft tissue injuries?
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Platelet-rich plasma (PRP) has become increasingly popular in
sports medicine and orthopaedic practice as treatment for
muscle, tendon, and ligament injuries, and has received media
attention because of its promise as a regenerative therapy.1 2
PRP is an autologous preparation of a patient’s whole blood,
which is centrifuged or filtered, allowing separation of a fraction
containing a supraphysiological concentration of platelets (fig
1⇓). PRP can be applied on its own, or as an adjunct to surgery,
allowing a high “dose” of growth factors and other bioactive
proteins such as cytokines and chemokines to be delivered to
the target tissue. This has the potential to improve repair and
regeneration, although evidence from in vitro and animal studies
has been conflicting.3-5
As an autologous preparation, PRP has been introduced into
clinical practice without being subject to the stringent
development required of new drugs. Many commercially
available PRP preparation devices have US Food and Drug
Administration (FDA) approval, although this is based on device
performance and safety, not on a requirement for evidence of
clinical efficacy.6
What is the evidence of uncertainty?
Lack of evidence of effectiveness
A 2014 Cochrane review identified 19 single centre randomised
trials (1088 participants) that compared PRPwith placebo, whole
blood, dry needling, or no treatment for eight different soft tissue
injuries, either as a direct treatment (for elbow lateral
epicondylitis, patellar tendinopathy, and Achilles tendon
tendinopathy) or as an adjunct to surgery (anterior cruciate
ligament reconstruction grafts and donor sites, rotator cuff repair,
subacromial decompression, and Achilles rupture repair).7
Comparisons with other active treatments were not included.
Most trials were judged to be at high risk of bias, with lack of
standardisation of PRP preparation. Overall, there was no
clinically significant improvement in pain and function with
PRP. The authors of the Cochrane review concluded that there
was insufficient evidence to support the use of PRP.
In our review of a further 10 randomised controlled trials (476
participants), we too had difficulty drawing clear conclusions
about the efficacy of PRP, because of heterogeneous
musculoskeletal conditions and outcome measures,
underpowered studies, and poor reporting. Only half of these
trials included analyses of PRP content and quality, and these
showed marked differences in platelet concentration and white
cell content; this is problematic, as different PRP preparations
and application techniques could affect effectiveness.2
Possible harms
Autologous PRP is generally considered to carry a low risk of
harm, but there are no high quality large scale clinical studies
evaluating safety.8 Pooled data from the Cochrane review did
not show a significant difference between PRP and comparator
groups.7 Use of PRP may risk introducing infection, reported
as an adverse event in two surgical randomised controlled
trials.9 10 A recent PRP randomised controlled trial found that
2/160 (1%) of PRP samples were positive for microbial growth,
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PRACTICE
What you need to know
• Autologous platelet-rich plasma (PRP) is increasingly used to treat musculoskeletal soft tissue injuries, either on its own or as an
adjunct to surgery
• Routine use is not recommended as there is insufficient evidence of clinical efficacy; instead, its use should be restricted to research
settings
• Ensure patients receiving PRP are aware of the limited evidence of efficacy, so that they can make an informed decision about their
care
• Clinicians should be aware of the concentration of PRP, and yield of bioactive proteins, produced by their selected preparation device
Search strategy and study selection
We used the same search strategy and eligibility criteria as a Cochrane review of PRP (randomised controlled trials of platelet-rich plasma
(PRP) versus no PRP or placebo)7 in Medline and the Cochrane Library and Central Register Of Controlled Trials (up to 27 May 2015). We
found a further 10 randomised controlled trials (476 participants), investigating PRP use for rotator cuff tendinopathy15 16 and surgical repair,9-20
acute hamstring injury,11 21 and elbow lateral epicondylitis.22
although no clinical indicators of infection developed.11 Infection
risk may also vary with different PRP preparations as some
have been shown to have antimicrobial properties in vitro.12
Is ongoing research likely to provide
relevant evidence?
We searched the WHO International Clinical Trials Register
and identified several ongoing randomised controlled trials
evaluating PRP for a wide range of musculoskeletal soft tissue
injuries. We are currently conducting the PATH-2 study, a
randomised controlled trial to compare the effects on
muscle-tendon function of a standardised PRP preparation versus
dry needle injection (control) for non-operatively managed acute
Achilles tendon rupture (ISRCTN54992179).
What should we do in the light of the
uncertainty?
Routine use of PRP in clinical practice for musculoskeletal soft
tissue injuries cannot be recommended given the lack of high
quality clinical evidence supporting its efficacy. Thus the UK's
National Institute for Health and Care Excellence (NICE)
guidance for autologous blood injections, including PRP, for
plantar fasciitis and tendinopathy states that it should “only be
used with special arrangements for clinical governance, consent
and audit or research,” even if there are nomajor safety concerns
with use for these conditions.13 14
We argue that patients should only be offered PRP for
musculoskeletal soft tissue injuries within the context of well
designed clinical trials, with informed consent, high quality
verbal explanations, and supporting written information. Advise
patients that there is currently insufficient evidence to show that
it is effective treatment for musculoskeletal soft tissue injuries.
Clinicians offering PRP should ask manufacturers for the
evidence of the platelet and growth factor concentrations, the
constitution, and the viability of their PRP product (platelet
activation levels).
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Recommendations for further research
Large multicentre randomised controlled trials with blinding of participants, outcome assessors, and where practical, clinical investigators
—Patients with common high-burden musculoskeletal soft tissue injuries, receiving either platelet-rich plasma (PRP) or a placebo or
inactive control intervention. Efficacy of PRP should be established before comparisons with other active interventions.
Outcome measures—Pain, patient reported function scales, physical performance tests, and return to sport, work, and social activities.
Trials should also evaluate:
• What cell and growth factor concentrations and platelet activation levels in PRP optimise clinical efficacy
• Optimal preparation process and delivery method for PRP (for example, whether injections need to be guided by imaging for some
conditions)
• Specific timing or dose of PRP, or need for repeated injections
• Which validated clinical outcomes (such as recovery of musculoskeletal function) and outcomes important to patients (such as pain
and longer term risk of re-injury) are the most appropriate
• The risk of adverse events, with careful monitoring and reporting of harms.
Large scale collaboration are needed to facilitate multicentre randomised controlled trials, expanding networks of clinicians and
researchers.23
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Figure
Fig 1Making autologous platelet-rich plasma (PRP): a whole blood sample is taken (a) then a specialised centrifuge (such
as the Magellan Autologous Platelet Separator System from Arteriocyte (b)) or filtration system is used to concentrate the
platelets, and the resulting PRP is collected in a syringe for injection into the target tissue (c)
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